Ligand Pharmaceuticals (LGND) Gross Profit (2010 - 2026)

Ligand Pharmaceuticals has reported Gross Profit for 17 years, with the latest figure at $48.4 million in Q1 2026.

• Quarterly Gross Profit rose 19.67% year-over-year to $48.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $261.5 million (up 55.24% YoY) and the FY2025 annual result came in at $253.5 million, up 62.46% from the prior year.
• Gross Profit fell to $48.4 million in Q1 2026 per LGND's latest filing, from $56.7 million in the prior quarter.
• Over five years, Gross Profit peaked at $111.7 million in Q3 2025 and troughed at $24.7 million in Q2 2023.
• A 5-year average of $42.5 million and a median of $40.0 million in 2024 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2022 and 2025: Gross Profit tumbled 35.24% in 2022, then surged 126.2% in 2025.
• Over 5 years, Gross Profit stood at $28.8 million in 2022, then decreased by 8.02% to $26.5 million in 2023, then soared by 51.08% to $40.0 million in 2024, then soared by 41.77% to $56.7 million in 2025, then slipped by 14.51% to $48.4 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $48.4 million, $56.7 million, and $111.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.